​Ironwood Pharmaceuticals (IRWD) Gains From Strong Fiscal Q1 2026 Earnings Momentum

​Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has gained more than 14.72% over the past month, and Wall Street expects more than 38% upside from the current level. The stock also ranks as one of the Best Rising Penny Stocks to Buy According to Wall Street Analysts.

​Much of the gains are driven by healthy momentum from fiscal Q1 2026 earnings released last month on May 7. During the quarter, Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) reported $106.51 million in revenue and topped the expectations of $92.1 million. The growth was driven by a 97% year-over-year increase in the US LINZESS net sales, which reached $272.5 million. Management noted that the drug sales improved due to a strategic 50% list price reduction that eliminated costly inflationary rebates and boosted net pricing.

​Investors remain concerned regarding the company’s heavy reliance on LINZESS. On the bright side, the company remains on track to initiate the confirmatory Phase 3 STARS-2 clinical trial for Apraglutide in the second quarter of 2026. Moreover, management reiterated its 2026 outlook, projecting total revenue between $450 million and $475 million and adjusted EBITDA exceeding $300 million.

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) is a biopharmaceutical company focused on developing and commercializing transformative therapies for gastrointestinal (GI) and rare diseases.

While we acknowledge the risk and potential of IRWD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IRWD and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: Top 10 Large-Cap Stocks to Invest In At 52-Week Lows and 12 High Growth Semiconductor Stocks to Buy Now. 

Disclosure: None. Follow Insider Monkey on Google News.

1281292 - 11759070 - 1